Shirasawa, Masayuki
Yoshida, Tatsuya http://orcid.org/0000-0003-4896-5824
Shiraishi, Kouya http://orcid.org/0000-0002-5821-7400
Goto, Naoko
Yagishita, Shigehiro
Imabayashi, Tatsuya
Matsumoto, Yuji
Masuda, Ken
Shinno, Yuki
Okuma, Yusuke http://orcid.org/0000-0001-5743-0149
Goto, Yasushi
Horinouchi, Hidehito http://orcid.org/0000-0001-9090-801X
Yotsukura, Masaya
Yoshida, Yukihiro
Nakagawa, Kazuo
Naoki, Katsuhiko
Tsuchida, Takaaki
Hamamoto, Ryuji http://orcid.org/0000-0002-2632-1334
Yamamoto, Noboru
Motoi, Noriko http://orcid.org/0000-0001-7098-3311
Kohno, Takashi
Watanabe, Shun-ichi
Ohe, Yuichiro
Article History
Received: 3 July 2023
Revised: 26 August 2023
Accepted: 5 September 2023
First Online: 20 September 2023
Change Date: 3 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-023-02481-x
Competing interests
: Dr. TY reports grants from Takeda, Daiichi-Sankyo, AbbVie, and Bristol-Myers Squibb; grants and personal fees from Ono, Novartis, Merck Sharp & Dohme, and Amgen; and personal fees from AstraZeneca. KK reports personal fees from Chugai, ArcherDX, Eli Lilly, Roche, and Taiho outside the submitted work. Dr. YM reports grants from Grant-in-Aid for Scientific Research on Innovative Areas, Hitachi, Ltd., the National Cancer Center Research and Development Fund, and Olympus, and personal fees from AstraZeneca. Drs. MS, KS, NG, SY, TI, KM, MY, YY, K Nakagawa, and S-iW declare no competing interests. Dr. YS reports grants from Janssen and Japan Clinical Research Operations. KK reports personal fees from AstraZeneca, Bristol-Myers Squibb, Chugai, Eli Lilly, and Ono outside the submitted work. Dr. YO reports grants from AbbVie, grants from Roche, and personal fees from Bristol-Myers Squibb Grants, Nippon Boehringer Ingelheim, and AstraZeneca. KK reports personal fees from Chugai, Eli Lilly, Ono Pharma Co. Ltd., Taiho, and Pfizer Taiho Pharma Co. Ltd., outside the submitted work. Dr. YO reports grants from AbbVie, Bristol-Myers Squibb Grants, Kyorin, and Preferred Network; and grants and personal fees from AZK, Daiichi-Sankyo, Eli Lilly, Ono, Novartis, and Pfizer; and personal fees from AstraZeneca. KK reports personal fees from Boehringer Ingelheim, Chugai, Guardant Health Inc., Illumina, Merck Sharp & Dohme, Taiho, and Thermo Fisher outside the submitted work. Dr. HH reports grants and personal fees from Chugai, Ono, and Roche; grants from AbbVie, Bristol-Myers Squibb, Daiichi-Sankyo, Genomic Health, Janssen, and Merck Biopharma, and personal fees from AstraZeneca. KK reports personal fees from Merck Sharp & Dohme, Novartis, Eli Lilly, and Kyowa-Kirin, outside the submitted work. Dr. K Naoki reports personal fees from AstraZeneca, Chugai Pharmaceutical, Bristol-Myers Squibb, and Nippon Boehringer Ingelheim outside the submitted work. Dr. TT reports grants from Japan Agency for Medical Research and Development, and Foundation for Promotion Cancer Research Grant for Medical Research, and personal fees from Nippon Medical School Foundation, outside the submitted work. Dr. RH reports grants from JST AIP-PRISM (Grant Number JPMJCR18Y4), from null, outside the submitted work. Dr. Yamamoto reports grants from Chugai, Taiho, Eisai, Lilly, Quintiles, Astellas, BMS, Novartis, Daiichi-Sankyo, Pfizer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Bayer, ONO PHARMACEUTICAL CO., LTD, and Takeda; and personal fees from ONO PHARMACEUTICAL CO., LTD, Chugai, Eisai, Boehringer Ingelheim, and Cmic; and grants from Janssen Pharma, MSD, Merck, GSK, Sumitomo Dainippon, Chiome Bioscience Inc., Otsuka, Carna Biosciences, Genmab, TORAY, KAKEN, Shionogi, AstraZeneca, and Cmic; and personal fees from Eisai, Daiichi-Sankyo, MERCK, and Healios, outside the submitted work. Dr. RH reports grants from NEC and Ono, and personal fees from AstraZeneca, Chugai, MSD, Novartis, Roche, Daiichi-Sankyo, Takeda, Eli Lilly, and Janssen, outside the submitted work. Dr. TK reports grants from AMED, outside the submitted work. Dr. YO reports grants from Taiho, Eli Lilly, Kyorin, Daiichi-Sankyo, Dainippon-Sumitomo, Janssen, Kissei, LOXO, Novartis, and Takeda, and personal fees from AstraZeneca. KK reports personal fees from Amgen, AnHeeart Therapeutics Inc., Bayer, Bristol-Myers Squibb, Celltrion, Chugai, Kyowa-Hakko Kirin, Merck Sharp & Dohme, Nippon Kayaku, Ono Pharmaceutical Co., Ltd., Pfizer, Taiho, and Eli Lilly, outside the submitted work.
: The study was approved by the Ethics Committee of the National Cancer Center Hospital (2005-109, 2019-123). The written informed consent was obtained from each patient through the comprehensive consent form in the facilities. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.